Com­pass Ther­a­peu­tics touts tri­al suc­cess in bil­iary tract can­cer, but more da­ta are need­ed

Com­pass Ther­a­peu­tics said Tues­day that adding its bis­pe­cif­ic an­ti­body to chemother­a­py sig­nif­i­cant­ly im­proved re­sponse rates com­pared to chemother­a­py alone in a Phase 2/3 bil­iary tract …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER